{{item.title}}
{{item.text}}
{{item.text}}
Cyber recovery in a life sciences manufacturer has a second stage that many recovery plans don’t address. Although restoring systems returns them to technical availability, putting them back to work on GxP-regulated products requires documented evidence that the recovered environment remains fit for its intended use.
This distinction matters more as cyberattacks increasingly reach the medtech and pharmaceutical supply chain.
Cyberattacks aren’t new to this sector, but the rate and concentration have escalated sharply. Attacks on healthcare providers plateaued through the first half of 2026 while attacks on the businesses that supply them, a group that includes pharmaceutical and medical device manufacturers, kept climbing.
Recent incidents across pharma, medtech, and the broader life sciences supply chain disrupted ordering, manufacturing, and shipping.1 The disclosed impact widened in the weeks after the first announcement as companies assessed the full scope, and systems came back before operations did, with order backlogs and manufacturing catch-up continuing long after restoration.
Bringing plants and systems back up is a series of recovery milestones rather than one event. For GxP-regulated manufacturers, assurance work adds another milestone: establishing that recovered systems can return to GxP use. When an organization has not established the assurance path in advance, that work lands on the critical path.
Cyber recovery is planned against recovery time and recovery point objectives (RTO and RPO), which establish how fast a system returns to service and how much of its data can be recovered. Together, they define the technical recovery target.
GxP system readiness decisions, meanwhile, are made with different criteria: what changed during the incident and recovery, and what evidence is needed before the recovered environment can return to GxP use.
A technical restoration performed under an approved, pre-assessed recovery procedure may be supported by documented verification rather than a broader requalification effort. Recovery becomes more complicated when remediation changes system configuration, infrastructure, interfaces, data state, or other conditions on which validated operation depends. Those changes require an impact assessment, with assurance work scoped to risk, intended use, and the effect on product quality and patient safety.2 An assessment made at detection can be outdated by the time the full impact is known.
Evidence can also arrive slowly for legitimate reasons. A server may be held for forensic imaging before it can be rebuilt, and a database backup can be made available while its completeness and reconciliation still need assessment. Furthermore, the same infrastructure specialists are often split between containment, restoration, and evidence collection, straining the path to GxP readiness.
There’s also a disconnect between technical recovery and GxP use. IT recovery plans deliver a functioning environment, while Validation and Quality determine whether the recovered environment remains suitable for GxP use. Quality retains its approval and product-disposition responsibilities throughout, even when recovery work is led elsewhere. If IT, Validation and Quality haven’t agreed in advance on what evidence Quality needs, that question gets debated and settled during the incident. Production may be technically ready, but Quality can’t support release decisions.
Traditional validation programs handle controlled change well: a defined system or software release, a known scope, an approved change process, and assurance activities sized against a documented impact assessment. Cyber recovery arrives in a different form. Scope is uncertain at the outset, multiple systems may be affected at once, and impact assessments that normally run sequentially must run in parallel. In some cases, the remediation itself becomes the largest source of change.
In practice, cyber remediation can tighten privileged access, endpoint management, and identity controls. Endpoint management became one prominent example in March 2026, when CISA urged US organizations to harden configurations after an attack that, according to public reporting, used compromised administrative access to wipe managed devices.3
Because those controls can sit underneath multiple GxP applications, a significant revision to a shared identity or endpoint-management layer widens the impact-assessment boundary to the systems that depend on it, even where application code hasn’t changed. A change to single sign-on rules, for instance, can bring configuration and installation qualification checks, along with targeted risk-based regression, into every application the assessment identifies as dependent on those settings.
During an outage, sites resort to approved paper-based recordkeeping. Those records create another issue after restoration when they must be reconciled, entered into electronic systems where required, verified against contemporaneous source records, and retained under applicable procedures. The resulting electronic records carry the same GxP controls for authenticity, integrity, accuracy, and retrievability as any other.4 That workload grows with the outage, and where business continuity procedures are either poorly established or unrehearsed, the administrative recovery can outlast technical restoration.
Current GxP and software-assurance frameworks do not prescribe a single post-incident requalification path. They require organizations to apply what their quality systems should already encompass, including risk assessment, change and configuration control, validation status, data integrity, and a documented rationale for the assurance scope selected. EU GMP Annex 11 requires controlled changes to computerized systems and periodic evaluation to confirm that systems remain in a valid state and compliant with GMP expectations.5
This is where cyber recovery strains validation decision-making, since the avoidable delay comes from determining the assurance scope while the recovery clock is already running.
Regulators are asking the same questions, with the July 2025 draft revision of Annex 11 making cybersecurity substantially more explicit and expanding requirements for system security, identity and access management, backup, and periodic review.6 The consultation closed in October 2025. As of September 2026, the 2011 Annex remains the published version in EudraLex.
Scoping assurance work during an incident adds to the recovery timeline in three places—establishing what changed, completing the assurance work, and holding production or shipment decisions while the evidence is compiled. That last delay is the one customers feel. Your system can be technically restored and still not fit for GxP use. Until it is, product does not ship and nobody can give customers a date. Failure to revalidate before use is a compliance exposure in itself, and every record produced or batch released on that system can be challenged.
Establishing the assurance path in advance shortens the recovery timeline, limits the remaining work to what the incident truly warrants, and gives leadership a more defensible basis for estimating when regulated operations can resume.
This is a defined cross-functional project. Identify the release-gating systems, define the assurance path for each recovery scenario, align evidence requirements across Quality, IT, Security, and key vendors, and test the model through a joint recovery exercise. The result is a recovery plan that extends to GxP readiness rather than stopping at technical restoration, one that treats recovery as complete only when your organization can rely on a restored system for its intended GxP use and has the evidence to support that decision.
Our team works with life sciences and medical device manufacturers on validation strategy, quality systems, and cyber resilience, helping reduce the interval between technical restoration and return to GxP use by establishing the assurance paths, evidence requirements, and joint recovery exercises described here.
{{item.text}}
{{item.text}}